Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bernd W.
Bernd W. Mueller, Flintbek DE
| Patent application number | Description | Published |
|---|---|---|
| 20080227847 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use - The present invention relates to novel amino acid salts of fumaric acid monoalkylesters. The salts are suitable for use as active substances in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders. | 09-18-2008 |
| 20090304790 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 12-10-2009 |
Bernd W. Mueller, Peine DE
| Patent application number | Description | Published |
|---|---|---|
| 20100297599 | TRANSPARENT COOLING GEL - For cooling organs and tissues in transplantation medicine, only ice preparations are used so far which are not soft like a gel and are brought to the necessary degree of comminution by mechanically comminuting frozen, sterile, pyrogen-free isotonic infusion solutions, such as 5% glucose or 0.9% saline, with great effort. The lack of gel-like consistency of the preparations and the expensive production process are very disadvantageous. | 11-25-2010 |
Bernd W. Muller, Flintbeck DE
| Patent application number | Description | Published |
|---|---|---|
| 20090162340 | STABLE GALENIC FREEZE-DRIED PHARMACEUTICAL PREPARATION OF RECOMBINANT CARBOHYDRATE-BINDING POLYPEPTIDES - The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms. | 06-25-2009 |
Bernd W. Müller, Flintbek DE
| Patent application number | Description | Published |
|---|---|---|
| 20080299196 | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 12-04-2008 |
| 20100190706 | Stable Non-Aqueous Pharmaceutical Compositions - The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent. | 07-29-2010 |
Bernd W. Müller, Flintbek DE
| Patent application number | Description | Published |
|---|---|---|
| 20100190706 | Stable Non-Aqueous Pharmaceutical Compositions - The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia, comprising insulinotropic peptide and semi-polar protic organic solvent. | 07-29-2010 |
| 20110159102 | Apparatus and Method for Continuous Production of Spherical Powder Agglomerates - The disclosure relates to a process for continuously producing spherical powder agglomerates, in which morphologically irregular starting agglomerates of micronized pulverulent particles are rounded off continuously by application to a surface induced to vibrate. | 06-30-2011 |
Bernd W. Müller, Flintbeck DE
| Patent application number | Description | Published |
|---|---|---|
| 20110217283 | STABLE GALENIC FREEZE-DRIED PHARMACEUTICAL PREPARATION OF RECOMBINANT CARBOHYDRATE-BINDING POLYPEPTIDES - The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms. | 09-08-2011 |
Bernd W. Sandt, Midland, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20100015277 | Malolactic fermentation of wine - A method for improving the malolactic fermentation in wines comprising conducting the malolactic fermentation using lactic acid bacteria with organic alkaline or neutral dispersing agent. | 01-21-2010 |
Bernd W. Spur, Marlton, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110237669 | Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders - This invention relates to the identification and treatment of the effects of products derived from oxidative pathways for polyunsaturated fatty acid (PUFA) metabolism, i.e., oxidative stress in a patient by monitoring the metabolism of DHA or by administering DHA. | 09-29-2011 |